New immunotherapy cocktail tested for tough cancers
NCT ID NCT05661578
First seen Nov 03, 2025 · Last updated May 01, 2026 · Updated 34 times
Summary
This study tested a new combination of two immunotherapy drugs (tiragolumab and atezolizumab) given together as a single injection. The goal was to see if this fixed-dose combo is safe and how it works in the body for people with advanced solid tumors that have a specific marker (PD-L1). 64 participants took part in this phase 2 trial, which has already been completed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PD-L1-SELECTED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center - PPDS
Seoul, 05505, South Korea
-
C.H. Regional Reina Sofia - PPDS
Córdoba, 14004, Spain
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Chongqing Sanxia Central Hospital
Chongqing, 404000, China
-
Gazi University Medical Faculty
Ankara, 06500, Turkey (Türkiye)
-
General Hospital Pula
Pula, 52000, Croatia
-
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, 06100, Turkey (Türkiye)
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Regional Universitario de Malaga ? Hospital General
Málaga, 29010, Spain
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
IASO Obstetrics Gynecology Clinic
Marousi, 151 23, Greece
-
ICO l?Hospitalet ? Hospital Duran i Reynals
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Inonu University Faculty of Medicine Turgut Ozal Medical Center
Malatya, 44280, Turkey (Türkiye)
-
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, 8035, Spain
-
Klinicki bolnicki centar Zagreb
Zagreb, 10000, Croatia
-
Medical Oncology Associates
Spokane, Washington, 99208, United States
-
Medical Park Seyhan Hospital
Seyhan, 01060, Turkey (Türkiye)
-
Memorial Ankara Hastanesi
Ankara, 06520, Turkey (Türkiye)
-
Memorial Sisli Private Hospital
Istanbul, 34385, Turkey (Türkiye)
-
Namik Kemal University
Alt?nova, 59100, Turkey (Türkiye)
-
National Cancer Center
Goyang-si, 10408, South Korea
-
National Cheng Kung University Hospital
Tainan, 70457, Taiwan
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Oncology Institute of Vojvodina
Kamenitz, 21204, Serbia
-
Oncomed-System
Belgrade, 11000, Serbia
-
START MADRID_Hospital Universiario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC
Madrid, 28050, Spain
-
Seoul National University Bundang Hospital
Seongnam-si, 13605, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
St. Luke's Hospital
Thessaloniki, 552 36, Greece
-
TAIPEI VETERANS GENERAL HOSPITAL, Urology
Taipei, 11217, Taiwan
-
University General Hospital of Patras
Pátrai, 265 00, Greece
-
University Hospital Medical Center Bezanijska kosa
Belgrade, 11080, Serbia
Conditions
Explore the condition pages connected to this study.